Pulse Biosciences (PLSE) Corporate presentation summary

Mission and vision

• Aims to design, produce, and commercialize next-generation solutions using nsPFA technology to improve patient outcomes.

• Focuses on meeting the needs of patients, physicians, and healthcare providers with high-quality, reliable products.

• Strives to positively impact all stakeholders, including shareholders and team members.

Leadership and expertise

• Leadership team includes experienced technologists, operators, and clinicians from major medtech companies.

• Board of directors and scientific officers bring expertise in electrophysiology and cardiac surgery.

Financial and strategic position

• Cash and cash equivalents of $68.3 million as of March 31, 2026, with no debt.

• Cash burn increasing to support clinical opportunities; $14.6 million used in operating activities in Q1 2026.

• Q1 2026 revenue was $401,000; insider ownership is approximately 75%.

• Strategic focus on accelerating pivotal trial enrollment and evaluating EP partnership strategies.